Neal X Chen

List of Publications by Year
in descending order

58 papers	2,484 citations	218677 26 h-index	197818 49 g-index
58 all docs	58 docs citations	58 times ranked	2895 citing authors

#	Article	IF	Citations
1	Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney International, 2002, 62, 1724-1731.	5.2	297
2	High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrology Dialysis Transplantation, 2006, 21, 3435-3442.	0.7	159
3	Vascular Calcification: Pathophysiology and Risk Factors. Current Hypertension Reports, 2012, 14, 228-237.	3.5	150
4	Annexin-Mediated Matrix Vesicle Calcification in Vascular Smooth Muscle Cells. Journal of Bone and Mineral Research, 2008, 23, 1798-1805.	2.8	147
5	Arterial calcification in diabetes. Current Diabetes Reports, 2003, 3, 28-32.	4.2	142
6	A rat model of chronic kidney disease-mineral bone disorder. Kidney International, 2009, 75, 176-184.	5.2	136
7	Decreased MicroRNA Is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD). PLoS ONE, 2013, 8, e64558.	2.5	106
8	Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy. Journal of Bone and Mineral Research, 2015, 30, 499-509.	2.8	103
9	Matrix vesicles induce calcification of recipient vascular smooth muscle cells through multiple signaling pathways. Kidney International, 2018, 93, 343-354.	5.2	88
10	Fluid shear-induced NFÎºB translocation in osteoblasts is mediated by intracellular calcium release. Bone, 2003, 33, 399-410.	2.9	83
11	Pathophysiology of Vascular Calcification. Current Osteoporosis Reports, 2015, 13, 372-380.	3.6	83
12	The pathophysiology of early-stage chronic kidney diseaseâ€"mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. Journal of Bone and Mineral Research, 2011, 26, 2672-2681.	2.8	82
13	Activation of Arterial Matrix Metalloproteinases Leads to Vascular Calcification in Chronic Kidney Disease. American Journal of Nephrology, 2011, 34, 211-219.	3.1	76
14	Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease. PLoS ONE, 2016, 11, e0159411.	2.5	62
15	Adipocyte induced arterial calcification is prevented with sodium thiosulfate. Biochemical and Biophysical Research Communications, 2014, 449, 151-156.	2.1	61
16	Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins. American Journal of Physiology - Renal Physiology, 2007, 292, F599-F606.	2.7	55
17	Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. Kidney International, 2010, 77, 436-442.	5.2	51
18	Vascular calcification in chronic kidney disease. Seminars in Nephrology, 2004, 24, 61-68.	1.6	48

#	Article	IF	Citations
19	Cortical Bone Mechanical Properties Are Altered in an Animal Model of Progressive Chronic Kidney Disease. PLoS ONE, 2014, 9, e99262.	2.5	40
20	Differential miRNA Expression in Cells and Matrix Vesicles in Vascular Smooth Muscle Cells from Rats with Kidney Disease. PLoS ONE, 2015, 10, e0131589.	2.5	37
21	Transglutaminase 2 Accelerates Vascular Calcification in Chronic Kidney Disease. American Journal of Nephrology, 2013, 37, 191-198.	3.1	35
22	Effect of Advanced Glycation Endâ€Products (AGE) Lowering Drug ALTâ€711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKDâ€MBD. Journal of Bone and Mineral Research, 2020, 35, 608-617.	2.8	31
23	Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney International, 2011, 80, 612-619.	5.2	30
24	Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E594-E604.	3.5	30
25	RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC). American Journal of Physiology - Renal Physiology, 2010, 299, F674-F680.	2.7	29
26	Time course of rapid bone loss and cortical porosity formation observed by longitudinal Î¼CT in a rat model of CKD. Bone, 2019, 125, 16-24.	2.9	27
27	Uremic Vascular Calcification. Journal of Investigative Medicine, 2006, 54, 380-384.	1.6	24
28	Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract. , 2020, 30, 4-10.		24
29	Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. Bone, 2015, 77, 50-56.	2.9	23
30	Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model. Nephrology Dialysis Transplantation, 2016, 32, gfw274.	0.7	20
31	Raloxifene improves skeletal properties in an animalÂmodel of cystic chronic kidney disease. Kidney International, 2016, 89, 95-104.	5.2	19
32	Age and sex effects on FGF23-mediated response to mild phosphate challenge. Bone, 2021, 146, 115885.	2.9	19
33	The Role of the Synovium and Cartilage in the Pathogenesis of Î²2â€Microglobulinâ€ƒAmyloidosis. Seminars in Dialysis, 2001, 14, 127-130.	1.3	17
34	Low Bone Turnover in Chronic Kidney Disease Is Associated with Decreased VEGF-A Expression and Osteoblast Differentiation. American Journal of Nephrology, 2015, 41, 464-473.	3.1	17
35	Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease. Nephrology Dialysis Transplantation, 2015, 31, gfv352.	0.7	16
36	Effect of dietary phosphorus intake and age on intestinal phosphorus absorption efficiency and phosphorus balance in male rats. PLoS ONE, 2018, 13, e0207601.	2.5	14

#	Article	IF	Citations
37	Effect of ovariectomy on the progression of chronic kidney disease-mineral bone disorder (CKD-MBD) in female Cy/+ rats. Scientific Reports, 2019, 9, 7936.	3.3	14
38	Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Diseaseâ€“Mineral Bone Disorder. Journal of Bone and Mineral Research, 2020, 35, 333-342.	2.8	14
39	Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease. Bone, 2021, 143, 115632.	2.9	13
40	Subcutaneous nerve activity and mechanisms of sudden death in a rat model of chronic kidney disease. Heart Rhythm, 2016, 13, 1105-1112.	0.7	11
41	Regulation of reactive oxygen species in the pathogenesis of matrix vesicles induced calcification of recipient vascular smooth muscle cells. Vascular Medicine, 2021, 26, 585-594.	1.5	9
42	Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease. Bone, 2022, 157, 116340.	2.9	7
43	Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing. Bone, 2019, 127, 419-426.	2.9	6
44	N-acetylcysteine (NAC), an anti-oxidant, does not improve bone mechanical properties in a rat model of progressive chronic kidney disease-mineral bone disorder. PLoS ONE, 2020, 15, e0230379.	2.5	6
45	Predicting fracture healing with blood biomarkers: the potential to assess patient risk of fracture nonunion. Biomarkers, 2021, 26, 703-717.	1.9	5
46	Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD. Nephrology Dialysis Transplantation, 2022, 37, 1857-1867.	0.7	5
47	Adverse Effects of Autoclaved Diets on the Progression of Chronic Kidney Disease and Chronic Kidney Disease-Mineral Bone Disorder in Rats. American Journal of Nephrology, 2020, 51, 381-389.	3.1	4
48	Skeletal vascular perfusion is altered in chronic kidney disease. Bone Reports, 2018, 8, 215-220.	0.4	3
49	Skeletal muscle metabolic responses to physical activity are muscle type specific in a rat model of chronic kidney disease. Scientific Reports, 2021, 11, 9788.	3.3	2
50	<scp>Nonâ€Additive</scp> Effects of Combined <scp>NOX1</scp>/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Diseaseâ€Mineral and Bone Disorder (<scp>CKDâ€MBD</scp>). JBMR Plus, 2022, 6, e10600.	2.7	2
51	Single-cell RNA sequencing of intramedullary canal tissue to improve methods for studying fracture repair biology. BioTechniques, 2021, 71, 431-438.	1.8	1
52	Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease. Bone Reports, 2022, 16, 101174.	0.4	1
53	Reducing parathyroid hormone is essential for correcting cortical bone deficiencies associated with chronic kidney disease. FASEB Journal, 2013, 27, 967.10.	0.5	0
54	Treating Bone Quality in Chronic Kidney Disease. FASEB Journal, 2015, 29, 702.1.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0230379.		0
56	Title is missing!. , 2020, 15, e0230379.		0
57	Title is missing!. , 2020, 15, e0230379.		0
58	Title is missing!. , 2020, 15, e0230379.		0